Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
Psychedelic Drug Development Digital Summit

Psychedelic Drug Development Digital Summit

Categories

Date of beginning

Wednesday, 21 October 2020

Duration

2 days

City

Online

Country

United States

Contact

Psychedelic Drug Development Digital Summit

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

The use of psychedelic compounds has been met with controversy, and the industry faces unique barriers to development and access. As the burden of clinical efficacy evidence grows, the industry has seen an explosion in interest by pharma, biotech and the investment community. The inaugural Psychedelic Drug Development Digital Summit will gather the best and brightest minds harnessing natural and synthetic psychoactive substances to treat depression, addiction, anxiety and many more life debilitating psychiatric conditions. Join the Psychedelic Drug Development Summit to: • Optimize novel drug development in expanded indications with Psilera Bioscience, Sansero Life Science, and Eleusis Ltd. Investigate the fundamental biology of psychedelic drugs and how to apply this knowledge to therapeutic design • Advance your clinical success with AWAKN Life Sciences, DemeRX, The Beckley Foundation, and more. Hear industry consensus on clinical best practice, trial set up and scale, investigating novel indications and dose escalation to demonstrate safety and efficacy • Address stigma, discuss education, and drive policy change to deliver life-changing psychedelic therapies with MindMed, MAPS, Government organizations, and more. Learn how leaders are working to develop a robust to-market strategy in 2020 and beyond https://psychedelic-drug-development.com/ October 21-22, 2020 9am-3pm EST | 6am-12pm PDT | 2pm-8pm GMT Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. Prices:Industry Pricing - Earlybird rates available: USD 1600.0Academic Pricing - Earlybird rates available: USD 1100.0 Speakers: Amanda Feilding, Executive Director and Founder, The Beckley Foundation, Ben Sessa, Chief Medical Officer, AWAKN Life Sciences, Deborah Mash, CEO and Founder, DemeRX, George Goldsmith, CEO and Cofounder, COMPASS Pathways, Jacqueline von Salm, Co-Founder and CSO, Psilera Bioscience, Rick Doblin, Founder and Executive Director, MAPS Time: 2:00 pm - 8:00 pm